Aridis announces the closing of patient enrollment in the ar-301 global phase 3 superiority study

On track to complete data compilation and analyses, with top-line data expected to be announced in december '22 los gatos, calif. , oct. 4, 2022 /prnewswire/ -- aridis pharmaceuticals, inc. (nasdaq: ards) announced today that patient enrollment is closed in the ar-301 phase 3 clinical study.

ARDS Ratings Summary

ARDS Quant Ranking